Mineralys Therapeutics reported a wider-than-expected loss for the third quarter of 2026 as the company aggressively scales its commercial infrastructure. Management confirmed that preparations for the potential launch of lorundrostat are on track ahead of the FDA's PDUFA target date of December 22, 2026.
Key Highlights
- Net loss per share of $0.64 missed the consensus analyst estimate of $0.55 due to accelerated commercial spending.
- General and administrative expenses surged to $37.4 million, a 286% increase from the prior year, to fund the expansion of medical affairs and sales force teams.
- Cash, cash equivalents, and investments totaled $624.7 million as of September 30, 2026, which the company expects will fund operations into 2028.